Sanofi [NASDAQ: SNY] and GlaxoSmithKline [NYSE: GSK] today announced a supply deal for up to 60 million doses of COVID-19 vaccine with the UK government. Sanofi has developed a vaccine candidate in partnership with GlaxoSmithKline which is based on recombinant protein-based technology.
Sanofi [NASDAQ: SNY] leads the clinical development and registration of COVID-19 vaccine. Phase 1/2 study is expected to start in September and the phase 3 study expected to start by the end of 2020.
Shares of Sanofi dropped 0.69% and down -0.36 during the trading of Tuesday. During the past 52-weeks of trading, this company’s stock have fluctuated between the low of $37.62 and a high of $55.00. It has return on investment (ROI) of 3.50%.
Sanofi has Gross Margin of 68.00%, an Operating Margin of 16.20%, and Profit Margin of 13.60%. Sanofi’s trading volume is 1.54 million as compared to the average volume of 1.39 million.
On the other sides, GalxoSmithKline PLC has exhibited the change of 1.03% and up +0.42 during the trading of Tuesday. Its trading volume is 4.15 million as compared to the average volume of 3.12 million.
If we look at the profitability, it has return on assets (ROA) of 6.90%, return on investment (ROI) of 14.30%, and return on equity (ROE) of 54.00%. Its Gross Margin is 68.20%, and Operating Margin is 21.50%, and the Profit Margin of 15.30%.
Chair of the UK Government’s Vaccines Taskforce, Kate Bingham, said: “Through this agreement with GSK and Sanofi, the Vaccine Taskforce can add another type of vaccine to the three different types of vaccine we have already secured.”